mFOLFOX6 + HLX04 + serplulimab

A combination therapy regimen consisting of: 1. **mFOLFOX6**: A chemotherapy regimen containing oxaliplatin, leucovorin (folinic acid), and 5-fluorouracil (5-FU). The standard dosing includes: - Oxaliplatin 85 mg/m² IV over 2 hours - Leucovorin 400 mg/m² IV over 2 hours (concurrent with oxaliplatin) - 5-FU 400 mg/m² IV bolus - 5-FU 2400 mg/m² continuous infusion over 46 hours 2. **HLX04**: A bevacizumab biosimilar that targets vascular endothelial growth factor (VEGF) 3. **Serplulimab**: An immune checkpoint inhibitor This combination likely aims to provide multi-modal treatment by combining cytotoxic chemotherapy (mFOLFOX6), anti-angiogenic therapy (HLX04), and immunotherapy (serplulimab) for advanced cancers, particularly colorectal cancer.